Targeted Safety Data Collection Needs International Agreement, Industry Tells FDA
Executive Summary
FDA’s proposal to limit collection of certain safety data in late-stage and post-marketing clinical trials will only reduce the burden on sponsors, investigators and patients if drug regulators across the globe agree to the concept, pharmaceutical manufacturers say.
You may also be interested in...
FDA’s Temple Pushes Feasibility, Cost-Savings Of Large, Simple Trials
New tools and funding priorities support large, simple trials, now industry needs to get on board to create a more efficient, cost-effective health system, JAMA editorial says.
Large Simple Trials Need FDA Boost, IoM Report Says
“Clear specific guidance” from the agency would help close the perception gap between what types of data industry thinks FDA wants and what the agency actually expects, according to a summary of a 2012 Institute of Medicine workshop.
FDA’s Guide For Selectively Collecting Safety Data
A recent draft guidance reflects the agency’s views on when it may be appropriate to reduce the amount of safety information collected in late-stage and post-marketing studies and what types of data may be eligible for limited or non-collection.